Navigation Links
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson's Disease
Date:10/25/2012

ly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.

"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual pro
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  The board of directors ... declared a dividend for the second quarter of 2015 of ... The dividend is payable June 10, 2015, to shareholders of ... About Eli Lilly and Company Lilly is a global ... better for people around the world. We were founded more ...
(Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
(Date:5/4/2015)... May 4, 2015 PharmaEngine, Inc. (TWO:4162) ... Inc. (NASDAQ: MACK ) with its sublicensing ... jointly announced that Baxter has submitted a marketing ... (EMA) for MM-398 (irinotecan liposome injection), also known ... the pancreas who have been previously treated with ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
(Date:5/4/2015)... New Jersey (PRWEB) May 04, 2015 Parlin ... to give a chance to more youths to participate and ... encourage youths in her area to do good deeds and ... Dr.Blagoev intends to empower their minds and teach them to ... contest is accessible to any youth 18 years of age ...
(Date:5/4/2015)... May 05, 2015 The ... Irene Taylor , Volunteer Executive Director of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Patti Hommes as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... 2015 The National Association of ... as a 2015-2016 inductee into the NAPW VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor," said NAPW President Star Jones. "Her ...
(Date:5/4/2015)... May 05, 2015 The National ... Weis as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in healthcare. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” says NAPW President Star Jones. “Her ...
Breaking Medicine News(10 mins):Health News:10 More Days To Enter Good Deed Contest 2Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
The DOT-approved A150 test is used for workplace testing, most publicly for federally mandated testing of transportation workers, but also in private company "drug free workplace" programs. Each hash...
... QuickScreen multi-panel dip cards offer minimal exposure ... of any conceivable combination of 9 different ... your drug testing program. Just dip the ... timer tells you when to read the ...
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Medicine Products: